Our team of seasoned virologists, immunologists, and cellular biologists brings decades of experience to the table, possessing an in-depth understanding of viral pathogenesis, replication mechanisms, and antiviral drug discovery and development. We are well-versed in a wide range of in vitro and in vivo virology assays, capable of evaluating the efficacy, safety, and pharmacokinetic properties of potential antiviral compounds or therapies.
We offer a comprehensive suite of preclinical virology services tailored to meet the diverse needs of our clients, encompassing every stage of the research process:
Target Identification and Validation: We help you identify and validate novel antiviral targets, laying the foundation for effective drug discovery efforts.
Antiviral Compound Screening and Optimization: We employ a range of in vitro screening assays to identify promising antiviral candidates and optimize their potency and selectivity.
Efficacy and Safety Testing in Animal Models: We conduct rigorous efficacy and safety testing in animal models to assess the therapeutic potential of antiviral compounds while ensuring their safety profile.
Pharmacokinetic and Pharmacodynamic (PK/PD) Studies: We determine the absorption, distribution, metabolism, and excretion (ADME) properties of antiviral compounds, providing valuable insights into their pharmacokinetic profiles.
Regulatory Support and IND Preparation: We guide you through the intricate regulatory landscape, ensuring compliance with FDA guidelines and facilitating the preparation of Investigational New Drug (IND) applications.
Southern Research has a strong track record of translating our research findings into clinical practice. For example, Southern Research has played a key role in the development of several successful antiviral drugs, including:
Sofosbuvir: A first-in-class drug that revolutionized the treatment of hepatitis C virus (HCV) infection.
Remdesivir: A broad-spectrum antiviral drug that has been shown to be effective against a variety of viruses, including SARS-CoV-2 (COVID-19).
Southern Research is also at the forefront of research on emerging viral diseases and have BSL-2/3 lab capabilities. We are working to develop new diagnostic tools, treatments, and vaccines for these and other emerging threats.
